Navigation Links
Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
Date:10/23/2007

C International Conference on Molecular Targets and Cancer Therapeutics in a poster titled "A Phase 2 trial of SNS-595 in women with platinum refractory epithelial ovarian cancer," Abstract No. A158.

On Wednesday, October 24, 2007 at the AACR-NCI-EORTC meeting, Sunesis will present additional non-clinical data in a poster titled "SNS-595 potentiates the in vivo activity of carboplatin, cisplatin and gemcitabine in solid tumor xenografts," Abstract No. B285. This poster presentation will take place in Poster Session B -- Other Small Molecule Therapeutics.

About SNS-595

SNS-595 is a replication-dependent DNA damaging agent that causes irreversible G2 arrest and rapid apoptosis. A secondary mechanism for SNS-595 is a unique inhibition of topoisomerase II that causes highly selective DNA damage.

Data reported today build upon positive results from non-clinical studies, and from Sunesis' dose-escalating Phase 1 clinical trial of SNS-595 in which an ovarian cancer patient with advanced disease achieved a PR. In addition to the Phase 2 clinical trial in ovarian cancer patients, SNS-595 is currently being evaluated in two Phase 1b acute leukemia clinical trials. In clinical trials conducted to date, SNS-595 has been generally well tolerated and has shown objective responses in both solid and hematological tumor types. In non-clinical evaluations, SNS-595 demonstrates broad and potent activity in xenograft, syngeneic and drug-resistant models.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2007 there will be an estimated 22,430 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. The front-line treatment for ovarian cancer is typically a combination of a taxane and a platinum dru
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... PALO ALTO, Calif., July 23, 2014  Varian Medical ... net earnings of $1.02 per diluted share in the ... negatively impacted by about $0.06 per diluted share due ... a portion of Varian,s existing equity investment in Augmenix, ... Varian,s company-wide revenues totaled $748 million for the third ...
(Date:7/23/2014)... N.Y. , July 23, 2014 The ... VSCP ), a leading provider of clinical trial imaging ... 48, has been named president and chief executive officer, ... Directors in August 2013 and has held the positions ... 25, 2013. Dr. Charles E. Phelps ...
(Date:7/23/2014)... and MOUNTAIN VIEW, Calif. , July ... leader in translational preclinical research, today unveiled their new ... signaling the transformation of Surpass, corporate culture to one ... our customers. This press release comes on the heels ... were added to the Silicon Valley Team:  David Craig, ...
Breaking Medicine Technology:Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... 7, 2011 The U.S. Food and Drug Administration ... treat patients with late-stage (metastatic) head and neck cancer. ... Combined with chemotherapy, Erbitux extended the lives of ... chemotherapy alone. Erbitux already is FDA-approved for certain types ...
... Psychemedics Corporation, hair testing for drugs of ... announced today that its laboratory has received international ... of laboratory testing including drugs of abuse ... The International Organization for Standardization/International Electrotechnical Commission ...
Cached Medicine Technology:FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer 2FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer 3Psychemedics Awarded ISO/IEC 17025 International Accreditation 2Psychemedics Awarded ISO/IEC 17025 International Accreditation 3
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... for ATA 2015, ATA’s twentieth annual meeting and ... The meeting, expected to attract over 5,000 attendees ... will take place May 3-5, 2015, in Los ... most renowned healthcare technology professionals from researchers, clinicians, ...
(Date:7/23/2014)... ( FXS ) is a genetic disorder that causes ... autistic spectrum, as well as cognitive deficits. It is ... the most common cause of autism. , Now biomedical ... a study that sheds light on the ... (July 23) in the Journal of Neuroscience , ...
(Date:7/23/2014)... Olympic gold medal-winning speed skater Chad ... Friday, July 18. Hedrick visited Roanoke as the special ... an Olympic-style event celebrating its 25th Anniversary in 2014. ... premier sponsor of the Commonwealth Games, which like Foot ... and all activity levels. , Hedrick, a native of ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July 23, 2014 (HealthDay ... may be determined by hundreds, and possibly thousands, of gene ... over 100 regions of DNA that are connected to the ... researchers hope these findings will shed light on the biology ... to breast cancer. "These findings will provide additional insights ...
(Date:7/23/2014)... TX (PRWEB) July 23, 2014 Texas ... seven physical therapists from their Westlake, Westgate, Liberty Hill, ... earned the professional designation of Orthopaedic Certified Specialist ... this June. Adriana Juarez, PT, DPT, OCS, Tony Lauretta, ... Milligan, PT, DPT, OCS, Joseph Leech, PT, DPT, OCS, ...
Breaking Medicine News(10 mins):Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2Health News:Gene Study Gives New Insight Into Puberty in Girls 2Health News:Gene Study Gives New Insight Into Puberty in Girls 3Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3
... BIRMINGHAM, Ala. - New clinical data showed some cancer ... called AME-133v, said a researcher at the University of ... April 15th during the 2008 annual meeting of the ... Phase 1 clinical trial data showed AME-133v had a ...
... YORK, April 16 Jenni Schaefer, a young,woman ... with anorexia and,bulimia to become a well-known motivational ... girls everywhere, has been,appointed to the Ambassador Council ... a NEDA Ambassador, Schaefer will continue her travels ...
... April 16 Natural,Nutrition, Inc. (OTC Bulletin ... InterACTIVE Nutrition, Inc. (INII), http://www.interactivenutrition.com, achieved ... in EBITDA in the three month period ... exceeded the EBITDA requirements,for the company,s senior ...
... New NCPA,Study, DALLAS, April 16 The U.S. ... workers when they work,extra hours to get ahead, according ... Policy Analysis., "The impact on low-income workers and ... Kotlikoff, Boston University,professor and author of the study. "They ...
... are doomed to fail , , WEDNESDAY, April 16 (HealthDay ... household dust? Forget about it, a new study suggests. ... found that none was effective enough in reducing exposure ... The methods looked at included using chemicals to kill ...
... SAN DIEGO As potential cancer therapies proliferate, researchers ... to more accurately predict which patients will receive the ... Research 2008 Annual Meeting, April 12-16, 2008, researchers present ... cancer, how doctors can more effectively measure response to ...
Cached Medicine News:Health News:Jenni Schaefer, Motivational Speaker, Author Named National Eating Disorders Association (NEDA) Ambassador 2Health News:Natural Nutrition Subsidiary InterACTIVE Nutrition Reports First Quarter Revenue of $4,189,048 (CDN) and EBITDA of $504,500 (CDN) 2Health News:Tax Rates Mean Extra Work Doesn't Pay 2Health News:Dust Mites Trump Asthma Prevention Guidelines 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 3Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 4Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 5Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 6
... Enhanced features including aspiration holes and ... laparoscopic procedures requiring precise dissection with ... increased suction demands. ,Flexible design ... and nonretractable electrodes and multiple tip ...
... including aspiration holes and additional electrode ... requiring precise dissection with decreased risk ... demands. ,Flexible design options allow ... electrodes and multiple tip designs. Optimize ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: